These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38084090)

  • 1. Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
    Donaldson JM; Seddiq M; Fusco MJ; Singla S; Pamuk GE; Lee-Alonso RJ; Mixter BD; Goldberg KB; Amiri-Kordestani L; de Claro RA; Drezner N; Gormley NJ; Kanapuru B; Lemery SJ; Fashoyin-Aje LA; Richardson NC; Singh H; Suzman DL; Theoret MR; Kluetz PG; Pazdur R
    Cancer Discov; 2023 Dec; 13(12):2515-2524. PubMed ID: 38084090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gap between pediatric and adult approvals of molecular targeted drugs.
    Nishiwaki S; Ando Y
    Sci Rep; 2020 Oct; 10(1):17145. PubMed ID: 33051474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021.
    Kandemir EA
    J Oncol Pharm Pract; 2023 Jan; 29(1):191-207. PubMed ID: 35793068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the approval of cancer therapies by the FDA in the twenty-first century.
    Scott EC; Baines AC; Gong Y; Moore R; Pamuk GE; Saber H; Subedee A; Thompson MD; Xiao W; Pazdur R; Rao VA; Schneider J; Beaver JA
    Nat Rev Drug Discov; 2023 Aug; 22(8):625-640. PubMed ID: 37344568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).
    Elbaz J; Haslam A; Prasad V
    Cancer Med; 2024 Apr; 13(8):e7190. PubMed ID: 38659418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncology's trial and error: Analysis of the FDA withdrawn accelerated approvals.
    Preziosi AJ; Priefer R
    Life Sci; 2024 Jun; 346():122615. PubMed ID: 38582392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.
    Hirschfeld S; Ho PT; Smith M; Pazdur R
    J Clin Oncol; 2003 Mar; 21(6):1066-73. PubMed ID: 12637472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
    Cancer Discov; 2024 May; 14(5):890. PubMed ID: 38690602
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.
    Barone A; Casey D; McKee AE; Reaman G
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27809. PubMed ID: 31144772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Indications and Approvals for Anticancer Drugs.
    Aschenbrenner DS
    Am J Nurs; 2021 Dec; 121(12):16-17. PubMed ID: 34792500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program.
    de Claro RA; Gao JJ; Kim T; Kluetz PG; Theoret MR; Beaver JA; Pazdur R
    Clin Cancer Res; 2021 Jan; 27(1):11-14. PubMed ID: 32816899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
    Arora S; Narayan P; Osgood CL; Wedam S; Prowell TM; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Ghosh S; Philip R; Ison G; Berman T; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2022 Mar; 28(6):1072-1086. PubMed ID: 34711632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs.
    Zettler ME
    Expert Rev Anticancer Ther; 2022 Mar; 22(3):317-321. PubMed ID: 35051348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications.
    Cristina Mendonça Nogueira T; Vinicius Nora de Souza M
    Bioorg Med Chem; 2021 Sep; 46():116340. PubMed ID: 34416511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018.
    DeMartino PC; Miljkovic MD; Prasad V
    JAMA Intern Med; 2021 Feb; 181(2):162-167. PubMed ID: 33165499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. US Food and Drug Administration regulatory updates in neuro-oncology.
    Mehta GU; Barone AK; Bradford D; Larkins E; Kim J; Pai-Scherf L; Jaigirdar A; Shah M; Wedam S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA; Singh H
    J Neurooncol; 2021 Jul; 153(3):375-381. PubMed ID: 34156585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.